Download PDF
1 / Pages

Other users also viewed these articles

Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study Lidia Serrano Díaz; Carles Iniesta Navalón; Rosa Gómez Espín; Isabel Nicolás De Prado; Enrique Bernal Morell; Lorena Rentero Redondo;
Gastroenterol Hepatol. 2024;47:553-61
Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease Lidia Serrano Díaz; Carles Iniesta Navalón; Rosa Gómez Espín; Isabel Nicolás de Prado; Lorena Rentero Redondo;
Gastroenterol Hepatol. 2023;46:504-11
De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice Alex Arenas; María José Moreta; Ingrid Ordás; Agnès Fernández-Clotet; Berta Caballol; Marta Gallego; Alejandro Vara; Rebeca Barastegui; Angel Giner; Cristina Prieto; Maria Carme Masamunt; Roberto Candia; Elena Ricart;
Gastroenterol Hepatol. 2024;47:673-82